NLRP3 and cryopyrin-associated periodic syndrome: These results raise the possibility that MCC950/CRID3‐based therapies may need to be dosed at higher concentrations in CAPS patients to effectively treat inflammatory pathology than is needed to curb inflammatory pathology driven by wildtype NLRP3.